Global Health Updates: From New Cancer Treatments to IPO Insights

The report covers significant health news such as the FDA approval for an injectable cancer drug, Anthem Biosciences' IPO filing, bird flu outbreaks in France, and China's stance on COVID-19 data sharing. It also discusses lawsuits, advances in gene therapy, and planned medication price increases in the U.S.


Devdiscourse News Desk | Updated: 01-01-2025 02:29 IST | Created: 01-01-2025 02:29 IST
Global Health Updates: From New Cancer Treatments to IPO Insights
This image is AI-generated and does not depict any real-life event or location. It is a fictional representation created for illustrative purposes only.

The FDA has sanctioned an injectable form of Bristol Myers Squibb's cancer drug, Opdivo, as the agency continues to push the frontier of immune system-enhancing therapies known as PD-1 inhibitors.

In a significant financial move, Indian drugmaker Anthem Biosciences seeks to raise $397 million through an IPO, riding the momentum of a robust year for market listings. Key investors include True North and DavosPharma.

France loses its bird flu disease-free status following outbreaks on two poultry farms, reflecting a broader European trend. Meanwhile, China maintains its commitment to COVID-19 transparency amid WHO's calls for enhanced data sharing.

(With inputs from agencies.)

Give Feedback